Merck & Co., Inc. (FRA:6MK)
69.10
+2.20 (3.29%)
At close: Sep 30, 2025
Merck & Co. Revenue
Merck & Co. had revenue of $15.81B USD in the quarter ending June 30, 2025, a decrease of -1.90%. This brings the company's revenue in the last twelve months to $63.62B, up 1.82% year-over-year. In the year 2024, Merck & Co. had annual revenue of $64.17B with 6.74% growth.
Revenue (ttm)
$63.62B
Revenue Growth
+1.82%
P/S Ratio
3.30
Revenue / Employee
$848.21K
Employees
75,000
Market Cap
178.68B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 64.17B | 4.05B | 6.74% |
Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 78.30B |
Deutsche Telekom AG | 120.55B |
Allianz SE | 109.02B |
Rheinmetall AG | 10.67B |
Siemens Energy AG | 38.39B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
Deutsche Bank Aktiengesellschaft | 30.07B |
Merck & Co. News
- 4 days ago - Merck: Game-Changing Oncology Drugs Power Stock Surge - Seeking Alpha
- 5 days ago - Merck: 25% Total Return CAGR Potential - Seeking Alpha
- 7 days ago - Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery - Business Wire
- 8 days ago - FDA Clears Merck's One-Minute Cancer Shot - Benzinga
- 8 days ago - Price Over Earnings Overview: Merck & Co - Benzinga
- 8 days ago - Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds? - Nasdaq
- 8 days ago - Merck Snags A Key Approval Before Its Cash Cow Goes Off A Patent Cliff - Investor's Business Daily
- 8 days ago - Merck: Undervalued Pharma Stock With Defensive Approach And Compelling Dividend Yield - Seeking Alpha